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INTRODUCTION
In 1904 the doctor Archibald E. Garrod
described alkaptonuria, a disease he classified
as a lifelong congenital chemical alteration.
Later on, in 1909, he described other diseases:
albinism, cystinuria, porphyria and pentosuria,
which he named “Inborn Errors of Metabolism”.
Garrod’s conclusions were completely correct
in relation to the genetic basis of metabolic
disorders and the gene–enzyme concept.
1
According to Scriver, in the foreword of
“Physician’s Guide to the Laboratory Diagnosis
of Metabolic Diseases”,
2
 the importance of
Garrod’s observation that inborn errors of
metabolism (IEM) are manifestations of
biochemical individuality was never recognized
during his lifetime, nor has it been in our days,
because many doctors still think of IEM as
situations of extreme rarity that will never be
seen in the typical medical practice. IEM
produces manifestations in every organ, from
the fetus to geriatric l i fe and they are
omnipresent in appearance, not respecting the
doctor’s qualifications as a generalist or
specialist.
Inborn errors of metabolism cause
hereditary metabolic diseases (HMD) and
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classically they result from the lack of activity of
one or more specific enzymes or defects in the
transportation of proteins. The consequences
can usually be the accumulation of substances
present in small amounts, the deficiency of
critical intermediary products, the deficiency of
specific final products  or furthermore the
noxious excess of products of alternative
metabolic pathways.
3
The molecular basis of biochemical
disorders in HMD are genetic mutations in
enzymatic loci that affect activator proteins or
co-factors for enzymes, protein transportation,
carrier systems or recognition markers.
3,4
Incidence
More than three hundred human diseases
are known today that are caused by inborn
errors of metabolism and this number is
constantly growing because of new
identification techniques for the various
biochemical phenotypes. However, the
detection of HMD incidence has not been
increasing in parallel, probably because its
diagnosis is being underestimated. Faulty
diagnosis of IEM is related to a series of factors:
(1) they are individually considered rare and
therefore many physicians do not consider IEM
until most frequent conditions have been ruled
out, (2) blood and urine samples for
investigation of metabolic errors need to be
collected at the right time in relation to the course
of the disease, and (3) many metabolic diseases
only produce intermittent abnormalities.
3,5,6
IEM are not rare diseases when we observe
their cumulative incidence,
7
 which is about one
in every 5000 live births. Nevertheless, the
prevalence of each disease has many variables,
especially relating to race. Examples of frequency
for specific diseases include: 1 in 500 for familial
hypercholesterolemia;
8
 1 in 12,000 for
phenylketonuria;
4,9
 1 in 15,000 for organic
acidurias;
10
 1 in 60,000 for glycogen storage
diseases;
4
 1 in 45,000 for galactosemia;
8
 1 in
100,000 to homocystinuria
8
 and 1 in 290,000
for maple syrup urine disease.
11
In Brazil the incidence of some specific
IEM disorders have been found to be: 1 in
11,818 to 1 in 15,000 for phenylketonuria;
12,13
1 in 43,000 for maple syrup urine disease;
12
and 1 in 125,000 for biotin deficiency.
14
Inheritance Patterns
The majority of HMD are inherited
autosomal recessive traits, i.e. they have a
recurrence risk of 25% for each gestation of
heterozygous parents. Some diseases are X-
linked, that is, the mother is carrier of the
mutation, with the risk of recurrence for each
gestation in these cases being 50% for males
and 50% for females to be carriers of the
mutation who can pass it on to their children.
There are in addition mitochondrial diseases,
determined by mutations in mitochondrial DNA,
in which the risk of recurrence is virtually 100%
of the children of both sexes.
3
CLINICAL CLASSIFICATION OF INBORN
ERRORS OF METABOLISM
One of the most educational and clinical
classifications of IEM is to be found in The
Metabolic and Molecular Bases of Inherited
Disease, 1995 edition,
15
 by Saudubray &
Charpentier,
5
 which classif ies IEM in
accordance with the clinical phenotype and
presents tables of signs and symptoms and flow
charts that aid daily practice greatly. Table 1
shows a summary of the authors’ classification.
Category 1
Diseases that only affect a functional or
anatomical system or an organ, such as the
endocrine system, immune system, coagulation
factors or lipoproteins. The symptoms are
uniform and the correct diagnosis is usually
easy, because the basis of the biochemical
defect incorporates the given consequence, for
example, the tendency to bleed seen in cases
of coagulation defects.
Category 2
Diseases in which the biochemical basis
affects one metabolic pathway common to a great
Sao Paulo Med J/Rev Paul Med 1999; 117(6):251-65.
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number of cells or organs, such as in storage
diseases due to lysosomal disorders, or is restricted
to one organ with humoral and systemic
consequences, such as hyperammonemia in
defects of the urea cycle or hypoglycemia in
hepatic glycogenesis.
Diseases in this category have great
clinical diversity. The central nervous system
(CNS) is frequently attacked and in the evolution
of the disease many secondary abnormalities
can appear, making the diagnosis more difficult.
This category includes many errors in
intermediary metabolism (carbohydrate defects;
amino acid or organic acid metabolism with
primary or secondary disturbances of vitamin
or metal homeostasis; purine and peroxisome
disorders), diseases of intracellular transport
(endoplasmic reticulum and Golgi apparatus
defects) and lysosomal disorders.
These diseases can be divided into three
groups from a physiopathological perspective,
greatly assisting in diagnostic reasoning.
Group I
Disturbances in the synthesis or catabolism
of complex molecules. The symptoms are
permanent, progressive, independent of
incidental events and are not related to
alimentary ingestion.
Lysosomal Disorders. Also called storage
diseases. These lead to the progressive
accumulation of undigested substrates, usually
polymers, that cannot usually be hydrolyzed.
The polymers accumulate in lysosomes, where
they can be seen using optical or electron
microscopy. The affected tissues are those in
which the substance is usually catabolized in
great quantities: circulating lymphocytes,
fibroblasts, liver, spleen, conjunctiva, bone
marrow and intestinal mucosa. The clinical
manifestations in this group are generally
hepatomegaly or hepatosplenomegaly;
dysmorphic features (coarse facial features) that
are present at birth (GM1
 
gangliosidosis) or
develop in the first years of life (mucopo-
lysaccharidosis); ophthalmological, bone, joint
and central nervous system (CNS) involvement.
Table 2
4
 lists lysosomal disorders.
Peroxisomal Biogenesis Disorders.
Involving many anabolic functions. These
include the biosynthesis of plasmalogen, which
is a major myelin component, cholesterol and
bile acids. Generalized peroxisomal β-oxidation
deficiency results in a variety of disturbances
that are still not well understood, partly because
there is an overlap in function between the
peroxisomes and other organelles such as the
mitochondria and the endoplasmic reticulum.
These multiple and complex biochemical
abnormalities result in specific defects of
neuronal migration with malformations and
severe neurologic dysfunction, hypotonia,
mental retardation and developmental
regression. In contrast to lysosomal disorders,
there is no intracellular accumulation of
undigested polymers. A useful marker for their
diagnosis is the accumulation of very long chain
fatty acids in plasma, such as X-linked
adrenoleukodystrophy (“Lorenzo’s oil disease”).
Table 2
4
 lists the diseases in this group.
Defects In Intracellular Transport. Involving
defects in intracellular transport and protein
processing. This group includes α1-antitrypsin
deficiency and carbohydrate-deficient
glycoprotein syndrome.
Group 2
Inborn errors of intermediary metabolism
leading to acute and recurrent intoxication
(metabolic acidosis, vomiting, lethargy,
dehydration, thromboembolic complications) or
Sao Paulo Med J/Rev Paul Med 1999; 117(6):251-65.
Table 1 - Clinical classification of
inborn errors of metabolism
5
Category 1 Involving a functional system
Category 2 Affecting metabolic pathways common
to a great number of cells or organs
     Group 1 Defects in the synthesis or catabolism
of complex molecules
     Group 2 Defects in the intermediary metabolism
     Group 3 Deficiencies in energy production or
utilization
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chronic and progressive intoxication
(developmental delay or ectopia lentis) from the
accumulation of toxic compounds proximal to
the metabolic block. In this group are the
aminoacidopathies, organic acidurias, urea
cycle defects and sugar intolerance. The main
characteristics of this group are the existence of
periods free from symptoms and the relationship
with alimentary ingestion. The clinical expression
is late-starting, intermittent or related to the
introduction of the noxious substratum. Table 3
4
lists the diseases in this group.
Group 3
Energy deficiency diseases. The symptoms
are at least partially caused by deficiency in
energy production or utilization resulting from
Table 3 - Clinical classification of
inborn errors of metabolism
5
* - Group 2
Disorders of amino acids Cystinuria
Phenylketonuria
Tyrosinemia
Homocystinuria
Non-ketonic hyperglycinemia
Maple syrup urine disease
Organic acidurias Isovaleric acidemia
3-methylcrotonyl-CoA
carboxylase deficiency
3-methylglutaconic acidemia
3-hydroxy-3-methylglutaric acidemia
Propionic acidemia
Methylmalonic acidemia
Multiple carboxylase deficiency
Glutaric acidemia, type I
Urea cycle defects Carbamoyl phosphate
synthetase deficiency
Ornithine transcarbamylase
deficiency
Citrullinemia
Arginosuccinic aciduria
Argininemia
Lysinuric protein intolerance
Sugar intolerances Classical galactosemia
Galactokinase deficiency
Epimerase deficiency
Hereditary fructose intolerance
Hereditary fructose-1,6-
biphosphatase deficiency
*Modified
Table 2 - Clinical classification of
inborn errors of metabolism
5
* - Group 1
Lysosomal disorders
Mucopolysaccharidosis (mps) I-H - Hurler
I-HS - Hurler - Scheie
I-S - Scheie
II - Hunter
III - Sanfilippo
IV - Morquio
VI - Maroteaux - Lamy
VII - Sly
Sphingolipidoses GM1 Gangliosidosis
Tay - Sachs
Sandhoff
Fabry disease
Shindler disease
Lactosylceramidosis Gaucher disease
Farber disease
Nieman-pick disease
Krabbe disease
Metachromatic leukodystrophy
Multiple sulfatase deficiency
Mucolipidoses
Glycoproteinoses Fucosidosis
Manosidosis
Sialidosis
Aspartylglucosaminuria
Disturbances of membrane transport Sialic acid storage disease
Salla disease
Cystinosis
Others Ccarnavan disease
Pompe disease
Acid lipase deficiency
Peroxisomal biogenesis disorders Zellweger syndrome
Adrenoleukodystrophy
Refsum disease
Hyperoxaluria, type I
*Modified
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defects in intermediary metabolism in the liver,
myocardium, muscles or brain. This group
includes glycogenosis, glyconeogenesis defects,
congenital lactic acidemias, fatty acid oxidation
defects and mitochondrial diseases. The
diseases of this group present overlapping
clinical manifestations that may result in the
accumulation of toxic components or deficiency
in energy production.
The common symptoms include hypo-
glycemia, hyperlacticemia, severe generalized
hypotonia, myopathy, cardiomyopathy, growth
retardation, cardiac failure, circulatory collapse
and sudden infant death syndrome. Congenital
malformations indicating abnormal processes in
fetal energy pathways are also in this group, as
observed in pyruvate dehydrogenase complex
deficiency. Table 4
4
 lists the diseases in this group.
 CLINICAL MANIFESTATIONS
Neonatal Period And Childhood
The clinical findings for patients with HMD
presenting life-threatening acute metabolic crises
are nonspecific and include poor feeding,
vomiting, dehydration, lethargy, hypotonia and
seizures. This picture is similar to that of
septicemia, which may also be present, since
IEM predisposes to infectious conditions. When
a child with undiagnosed HMD dies, this fact is
attributed in general only to the sepsis, resulting
in an error of diagnosis. The autopsy findings
in such cases are frequently nonspecific, not
allowing for the diagnosis of a HMD.
5,6
There are some symptoms that are unusual
in HMD, like the case of inspiratory stridor in
an 11-month-old boy
16
 that became
progressively worse over a period of 4 weeks,
needing assisted ventilation. Ethylmalonic-adipic
aciduria was diagnosed, a mild variant of
multiple acyl-CoA dehydrogenation. The child
greatly improved with riboflavin supple-
mentation. The authors suggest research into
organic aciduria in the presence of unexplained
laryngeal stridor.
16
 There is furthermore a
description of transitory visual symptoms in a
Table 4 - Clinical classification of inborn errors of metabolism
5
* - Group 3
Fatty acid oxidation defects Medium chain  acyl-CoA dehydrogenase deficiency
Long chain  acyl-CoA dehydrogenase deficiency
Short chain  acyl-CoA dehydrogenase  deficiency
Long chain 3-OH-acyl-CoA dehydrogenase deficiency
Multiple acyl-CoA dehydrogenase deficiency (glutaric acidemia, type II)
Carnitine plasma  transport defect
Carnitine palmityl transferase deficiencies
Mitochondrial disorders Pyruvate dehydrogenase complex deficiency
Oxidative-phosphorylation (respiratory chain) defects (MERRF) (MELAS)
Pyruvate carboxylase
Phosphoenolpyruvate carboxykinase deficiency
Glycogen storage disorders HEPATIC FORMS Type 0; I; III; IV; VIII; IX; X
MUSCLE FORMS Type V; VII
*modified
Table 5 - Clues suggesting an inborn error of metabolism
3,6
Positive family history Metabolic acidosis
Consanguinity Neutropenia and/or thrombocytopenia
Loss of developmental milestones Hepato and/or splenomegaly
Siblings with unexplained infant/neonatal death Unusual  odor (urine or sweat)
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patient with X-linked adrenoleukodystrophy as
an initial manifestation of the disorder.
17
Among the clinical findings of HMD there
are descriptions of dysmorphic features present
at birth,
18
 generally when fetal energy is
affected,
2,5 
or developed during the first years
of life as in lysosomal diseases.
19
Clinical experience of HMD has shown
that when we have difficult or peculiar cases
that cannot be explained by known disease
physiopathologies, we should think of IEM as
an etiology, because there is probably a very
large variety of symptoms beyond those that
have been described. When we talk about the
clinical picture of HMD, it is always in a general
way, because within one disorder there is
individual variation in symptoms and severity.
Table 5
3,6
 lists clues suggesting an IEM and Table
6 lists frequent signs and symptoms in neonates
and infants.
6, 18, 20
Clinical Manifestation - Adult Life
The clinical manifestations of IEM are not
limited to childhood and adolescence: they
can also appear in adult life.
21
 Patients
detected via neonatal screening tests, who
receive early treatment, progress to adult life
with a series of complications and incidental
symptoms as a consequence of base diseases
such as phenylketonuria,
21,23
 or may present
a greater longevity as in cystic fibrosis,
24
 but
whatever the case, they will need to seek
general medical care.
Pregnant mothers with phenylketonuria face
problems in that they need rigorous diet control
so as not to affect the fetus.
24-30
 There are also
women who have hyperphenylalaninemia
without phenylketonuria and do not need to diet
because the phenylalanine levels do not harm
them. However, these levels are sufficiently
elevated during pregnancy to provoke
microcephaly or mental retardation in the fetus,
and so these women also are going to need diet
control.
31,32
Therapeutic progress in glycogen storage
disease, especially after uncooked cornstarch
therapy,
34
 has decreased the need for hepatic
transplantation and consequently the numbers
of individuals that survive until adult life have
been increasing.
35,36
In addition to cases of individuals detected
in the neonatal or childhood periods such that
they can reach adult life, as described above,
there is HMD that is only diagnosed in adult
life. This may occur because of one of the
following reasons:
1. Mild clinical manifestations in childhood and
adolescence. Examples:  propionic acidemia
in a boy that had vomiting in childhood for
2-3 days, improved with fasting at home
without medical attendance and in adult life
presented chorea and progressive
dementia;
37
 patients with hereditary fructose
intolerance who developed an aversion to
Table 6 - Clinical manifestations of  hereditary metabolic diseases in neonates and infants
6,18,20
Failure to thrive Vomiting and/or  diarrhea
Lethargy or coma Hypo or hypertonicity
Seizures Hepatomegaly and/or  hepatopathy
Respiratory distress and/or apnea Jaundice
Grotesque facial features Unusual odor (urine, sweat)
Dysmorphic features Abnormal hair
Macroglossia Abnormal eye findings*
Growth failure Myopathy
Frequent infections Development delay
Symptom-free interval Recurrent disturbances
*Cataract, retinopathy and others
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sweet food, then spending the whole life
without symptoms until fructose-containing
solutions were used during a surgery, when
the patient had a severe metabolic crisis;
38-
43
 hyperammonemia episodes, even fatal,
especially in women receiving protein
overload or under stress, as in childbirth,
because they are carriers of the ornithine
transcarbamylase (OTC) mutation, a urea
cycle defect of X-linked inheritance;
44-47
hyperammonemia coma  in two young
siblings with lysinuric protein intolerance,
both having been underweight with
intermittent gastrointestinal symptoms.
48
2. Diseases with clinical manifestation at the
onset of adulthood. Examples: alkaptonuria
involving large joints and spine in the third
or fourth decades of life;
40-51
 hypoglycemia
crisis in a young adult with glutaric aciduria
type II;
52
 glycogen storage disease type I,
normally detected in childhood, can be seen
in an adult with symptoms of hypoglycemia
53-
54
 or cardiomyopathy  in glycogen storage
disease  type II;
55
 McArdle’s disease or
glycogen storage disease type V
Table 7 - Clinical manifestations of hereditary
metabolic diseases in adult life
5
Progressive paraparesis Muscular weakness
Hemiparesis Ophthalmoplegia
Dystonia Visual deficit #
Epileptic crisis Behavioral disturbances *
Non myoclonic epilepsy Hepatomegaly and/or hepatopathy
Chorea Splenomegaly
Ataxia Hypoglycemia
# optical atrophy; cherry red spot; corneal opacities; * demen-
tia; depression; aggressiveness; psychosis; personality and char-
acter changes
Table 8 - Urine tests to inborn errors of metabolism
86-89
Benedict Galactosemia, fructose intolerances, alkaptonuria, Lowe syndrome. Positive also for: diabetes mellitus,
renal glycosuria, Fanconi syndrome, lactase deficiency, pentosuria, vitamin C excessive ingestion,
sulfonamides, tetracycline, chloramphenicol and p-amino salicylic acid
Ferric chloride Phenylketonuria, tyrosinemia, histidinemia,  maple syrup urine disease, hyperglycinemia, alkaptonuria.
Positive also for: pleochromocytoma, carcinomatosis, hepatic cirrhosis, transitory tyrosinemia,
conjugated hyperbilirubinuria, L-dopa metabolites, pyruvic acidosis,  salicylates, acetoacetic acid,
phenothiazines, methionine malabsorption, melanoma, lactic acidosis and isoniazide excretion
Dinitrophenylhydrazine Phenylketonuria, maple syrup urine disease, histidinemia, methionine malabsorption, hyperglycinemia,
glycogen storage diseases I, III, V and VI, lactic acidosis and  pyruvic acidosis
Nitrosonaphthol Hereditary tyrosinemia, transitory tyrosinemia, liver disease, fructosemia and galactosemia
p-nitroaniline Methylmalonic aciduria
Ctma bromide Mucopolysaccharidoses. Positive also for: Marfan syndrome, arthritis rheumatoid, cretinism
and carcinomatosis
Cyanide-nitroprusside Homocystinuria, cystinuria
Nitroprusside silver* Homocystinuria, cystinuria
Toluidine blue spot test* Mucopolysaccharidoses. Positive also for: Marfan syndrome, rheumatoid arthritis,
cretinism and carcinomatosis.
Erlich* Porphyria
Paper chromatography Disorders of amino acids
*These are not part of the minimum screening, but they should be done for confirmation as complementary tests, or in specific cases
such as porphyria.
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characterized by  exercise intolerance and
myoglobinuria,  usually appearing  from the
third decade of life;
56-62
 adult-onsetting Tay-
Sachs disease or gangliosidosis GM2
 
with
several variants with neuropsychiatric
manifestations;
64-67
 X-linked adrenoleu-
kodystrophy in the adult-onsetting form of
adrenomyeloneuropathy with progressive
paraparesis;
68-71
 Wilson’s disease or
hepatolenticular degeneration  can occur in
an adult with chronic hepatic cirrhosis
progressing to hepatic failure, renal
dysfunction, hemolytic anemia  and neuro-
logic symptoms such as dysarthria and
deterioration of voluntary coordination
movements;
72-74
 adult-onsetting Nieman-Pick
disease with progressive dementia,
dysarthria, ataxia and seizures starting from
the second or third decades;
75-76
 mitochon-
drial diseases can be adult-onsetting with
myopathy, encephalopathy, lactic acidosis
and stroke-like episodes;
77,78
 subacute
necrotizing encephalomyelopathy, Leigh’s
syndrome, in the juvenile form with chronic
sensory motor neuropathy, ataxia, deafness
and retinitis pigmentosa;
79
 cholesterol ester
storage disease variant diagnosed in two
unrelated women, 43 and 56 years with
chronic liver disease;
80
 the adult forms of
metachromatic leukodystrophy with
progressive mental deterioration as the first
symptom;
81
 hemochromatosis, usually
diagnosed in the fourth decade with cirrhosis,
arthritis, liver disease and diabetes;
82,83
amyloidosis with progressive dementia and
leukoencephalopathy;
84
 a new familial
leukodystrophy with dementia and abnormal
glycolipid storage
85
 among other diseases.
Table 7 lists the more common signs and
symptoms of adult-onsetting IEM.
5
DIAGNOSIS
The exact diagnosis of an HMD often
depends on specialized enzyme assays and/
or identification of molecular defect. These
methods are not very widely available,
especially in our country. Such tests are however
only suitable when there is a strong and more
specific suspicion of IEM diagnosis.
3,20
In fact, what is more important than the
exact tests for the HMD diagnosis is the clinical
judgement capable of leading towards a
probably safe diagnosis via identifying the
group that the disease belongs to. A lot of
information can be gained from the history,
physical examination, and more commonly
available laboratory tests, allowing the
treatment to be started as soon as possible,
when such therapeutic treatment exists.
3
The initial laboratory evaluation suggested
in the HMD literature varies in relation to the
Table 9 - Urinary odor in metabolic inherited disease
18,86
Disorder Odor Compound
Classical phenylketonuria Musty, mousy Phenylacetate
Hereditary tyrosinemia Musty, cabbage-like 2-hydroxybutyric acid
Rancid butter 2-oxo-4-methiolbutiric acid
Maple syrup urine disease Burnt sugar or 2-oxo-3-methylvaleric acid
Maple syrup 2-oxoisocaproic acid
Maggi curry 2-oxoisovaleric acid
Isovaleric Acidemia Sweaty feet or Isovaleric acid
3-Hydroxy-3-methylglutaric aciduria; multiple acyl-CoA dehydrogenation defects Cheese
3-Methylcrotonyl CoA carboxylase deficiency; multiple carboxylase deficiency Cat urine 3-hydroxyisovaleric acid
Methylmalonic acidemia Acid smell Methylmalonic acid
Cystinuria Sulfurous Hydrogen sulfide
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number and type of tests and it is generally
accomplished in a progressive way, according
to the results that are to be obtained, as
indicated below.
4-7,18,20,86
 The investigation of
an IEM could begin with simple urine and blood
tests (Table 8),
86-89
 because a negative urine
analysis does not rule out the HMD hypothesis
and the two screenings are complementary in
beginning the diagnostic reasoning.
Urine tests for IEM are not done very much
in major diagnosis centers, although they are
still of great importance for small laboratories
and in countries where higher technical
sophistication is not available. Some tests are
not specific, but a positive test can direct the
investigator towards one or more specific tests.
86
Looking at and smelling urine samples
should be routine practice for good metabolism
laboratories and Table 9 lists some peculiar
urine odors.
18,86
 Urine chromatography for
aminoacids
90
 or sugars form part of the initial
urinary tests.
The investigation of organic acids in urine
chromatography, mass spectrometry
91
 and
plasma amino acid analysis
92
 are requested in
accordance with clinical and laboratory
indications.
20
 All the urinary and plasma
analyses for IEM are influenced by the use of
medication such as acetaminophen, ampicillin/
amoxicillin, carbamazepine and the patient’s
state of health.
86,91,92
The blood tests
4-7,10,18,86
 include complete
blood count, blood gases, blood electrolytes
(Na, K, Cl, P, Ca), lactate, glucose, ammonia,
liver function testing, cholesterol, triglycerides,
pyruvate, urea, creatinine and uric acid. The
lactate/pyruvate ratio (normal < 25) is useful
in lactic acidosis, organic acidurias, urea cycle
defects and fatty acid oxidation defects. The
Anion Gap is fundamental [Na + K] – [HCO3- +
Table 10 - Clinical  findings in hereditary metabolic diseases
4
Clinical Manifestations Group of disorders
and Laboratory Findings A B C D E F G H     I
Episodic nature ++ ++ ++ ++ + + - - -
Poor feeding ++ + ++ + + + + - -
Abnormal odor + + - + - - - - -
Lethargy, coma + + + + + + - - -
Seizures + + + - + + + - +
Developmental regression - + + - + - + ++ +
Hepatomegaly + + + + + + + + +
Hepatosplenomegaly - - - - - - - + +
Splenomegaly - - - - - - - - +
Hypotonia + + + + + + + - +
Cardiomyopathy - + - + + + - + -
Grotesque facial features - - - - - - - ++ -
Hypoglycemia + + - + + + - - -
Metabolic acidosis + ++ - + + + - - -
Hyperammonemia + + ++ + - - - - -
Ketosis + + + - - + - - -
Hypoketosis - - - + - - - - -
Abbreviations: A = amino acidopathies; B = Organic acidopathies; C = Urea cycle defects; D = Fatty acid oxidation defects  E =
Mitochondrial disorders; F = Carbohydrate disorders; G = Peroxisomal disorders; H = Mucopolysaccharidoses; I = Sphingolipidoses
;++ = usually present; + = may be present  - = usually not present
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Cl
-
]: values of 12 ± 4 are considered normal,
and a value above 16 is suggestive of organic
aciduria.
93
Magnetic resonance imaging of the CNS
is generally superior to computed tomography
in HMD, allowing evaluation of the
demyelination that is frequent in these diseases.
Electroencephalography, electroretinography,
electromyography, cerebrospinal fluid analysis
and evoked potential are indicated in specific
cases.
27,28
The study of cells and tissues obtained via
biopsy has been particularly useful in the
characterization of many IEM: in the storage
diseases, establishing the nature of the
accumulated material; in diseases producing
alterations in the organelles such as
mitochondria or peroxisomes, performing
morphologic studies; and in diseases with tissue
markers suggestive of metabolic diseases. The
chronic hepatic diseases common to a series of
IEM are an example of the last group.
94
Table 9 lists a summary of clinical
manifestations and laboratory findings of some
groups more commonly found among hereditary
metabolic diseases, which may be helpful in
directing the diagnosis.
4
TREATMENT
The treatment of HMD depends on the IEM,
the clinical manifestation and the metabolites
accumulated that were responsible for the
patient’s decompensation. The combined
diagnostic and resuscitative measures do not
preclude a search for other etiologies. Complete
evaluation for sepsis is needed in neonates
because several HMD predispose towards
sepsis.
The basic principles for emergency
treatment management in patients who may
have an IEM can be summarized as follows:
3,7,20
1. Take appropriate diagnostic action: have
urine and blood samples collected to
investigate the IEM, as described above.
2. Treat acute metabolic decompensation such
as dehydration, metabolic acidosis,
hypoglycemia and, electrolyte disturbances.
3. Provide adequate calories and fluid to
prevent catabolism.
4. Remove toxic metabolites such as ammonia,
propionic and methylmalonic acid,
performing peritoneal or blood dialysis.
Blood exchange transfusion has been
performed in some centers where dialysis
could not be instituted. Increasing the
excretion of toxic metabolites can be
achieved by using alternative pathways, such
as sodium benzoate, phenylacetate, and
phenylbutyrate to improve the excretion of
waste nitrogen in hyperammonemia.
Carnit ine and glycine are useful for
eliminating organic acids. These can be
administered via nasogastric tube if
necessary.
5. Discontinue all protein and carbohydrate
(fructose or galactose) intake for about 24
hours, maintaining glucose and intravenous
lipid.
6. Supplement with indicated co-factors to
increase the residual enzyme activity when
possible, such as thiamin, riboflavin, biotin,
pyridoxine, cobalamin, and carnitine in
accordance with the disorder.
Once the acute crisis has been controlled,
attention must be turned to chronic management,
limiting the intake of the offending substance, if
possible, via manipulation of the diet. In
accordance with the diagnosis, formulas free
of certain amino acids, or restricting total protein
intake and specific carbohydrates could be
used.
Bone marrow transplantation has been
accomplished in some cases of mucopo-
lysaccharidosis, such as MPS I-H (Hurler), mild
variant MPS II (Hunter) and MPS V (Maroteux-
Lamy). Early transplantation leads to intelligence
level stabilization and disappearance of the
organomegaly, coarse facial features and the
chronic profuse watery rhinitis that is high in
glycosaminoglycans and could produce sleep
apnea. It also prevents heart manifestations. The
orthopedic problems are not prevented by the
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transplantation, but the progression in skeletal
involvement is slower. The transplant of bony
medulla is still indicated in metachromatic
leukodystrophy, adrenoleukodystrophy and
globoid cell leukodystrophy before the start of
clinical manifestations.
97-100
Enzyme replacement therapy in Gaucher
disease type I has resulted in gradual
normalization of blood counts, decrease in the
size of liver and spleen, and decrease in skeletal
symptoms. The results are better if the therapy
is early.
101-103
Enzyme replacement and gene therapy
represent the great hope in treatment for other
storage diseases, and are st i l l  at the
experimental stage, but it is hoped that they
may be used in the future.
104,105
Supportive treatment is very important in
reducing the morbidity of IEM and in giving
better quality of life even with the disorders that
do not have specific treatment.  In these cases,
orientation for supportive treatment is indicated
relating to general medicine, nutrition (to
provide appropriate caloric intake),
gastroenterology and speech therapy (for
evaluation of deglutive pharingo-esophageal
function and dysphagia), psychology (for the
family and patients) and physiotherapy.
15
IEM are hereditary in nature, and so the
family should have formal genetic counseling,
including prognosis for the patient, risk of
recurrence, possibility of prenatal diagnosis,
and screening of other family members,
especially for carriers of X-linked mutations.
3,7
BIOCHEMICAL BASIS FOR HEREDITARY
METABOLIC DISEASES - MINI REVIEW
The understanding of IEM is quite difficult,
especially while we still cannot fully visualize
the metabolism of the human organism as a
whole and the connections that exist among the
various metabolic reactions, which are crucial
in the maintenance of the basic functions of our
body.
Metabolism is basically energy production
and consumption, obeying certain priorities.
Energy is needed primarily for the basal rate of
metabolism, which is the energy spent by an
individual at rest and in an absorptive state for
the normal corporal functions such as breathing,
blood flow and maintenance of muscle integrity.
The thermal response to alimentary ingestion
may represent 5 to 10% of the total energy
expenditure for the body. Finally, physical
activity provides largest variation in energy
expenditure, with a highly active individual’s
energy expenditure being up to 100% greater
than the basal rate of metabolism.
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The largest deposits of energy in the
organism are glycogen and the triglycerides and
there are two priorities during fasting: (1) the
maintenance of plasma glucose levels for
cerebral metabolism and other tissues that
request glucose and (2) the need to mobilize
fatty acids from lipid storage and ketone bodies
from the liver so as to liberate energy for all
other tissues. In the absence of food, plasma
glucose, amino acid and triglyceride levels
drop, causing a decline in insulin secretion and
an increase in glucagon liberation. The low
insulin/glucagon ratio and the low availability
of circulating substrates create a catabolic state
during the period of nutrient deprivation,
characterized by triglyceride, glycogen and
protein degradation.
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The use of energy by our organism and
the metabolism during fasting mentioned above
refer to healthy adults. In children in a growth
phase and/or during an infection, there is a
significant increase in the basal rate of
metabolism. When there is an IEM in a child
with an infection, we may imagine the profound
metabolic alterations that occur and understand
the gravity of metabolic decompensation, with
its high mortality and great difficulty in
treatment.
108
All metabolic events are driven by
enzymes that are catalytic proteins and their
main function is to increase the speed of
reactions, without being altered during that
process. The enzymes possess a highly specific
active site that links to one or some specific
substrates and catalyzes only one type of
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chemical reaction. Some enzymes associate
with a co-factor (metallic ions or coenzyme)
needed for the enzyme activity.
96,107
Most IEM are a consequence of enzyme
deficiencies. In glycogen storage disease Type
I, for example, there is an inability to liberate
glucose from the liver, neither as a product of
glycogenolysis nor gluconeogenesis. Thus,
accentuated hypoglycemia occurs. During
fasting, the humoral response to hypoglycemia
provokes phosphorylase activation and hepatic
glycogenolysis. As there is no glucose liberation,
glycolysis continues with production of great
amounts of piruvate and consequently lactate.
The elevation of glycerol, acetyl-coenzyme A
and nicotinamide adenine dinucleotide (NADH)
levels generated by the increased flow in the
glycolytic pathway contribute to the increase in
triglyceride and cholesterol synthesis. The
glucagon stimulus mobilizes outlying reserves
of fat, elevating the circulating levels of free fatty
acid. Therefore, innumerable metabolic
alterations occur as a consequence of enzyme
deficiency and obviously in the case of a child
in a growth phase and with a larger number of
viral or bacterial infections, the control of these
disturbances is worse.
109
CONCLUSION
IEM are frequently underestimated by the
doctor in neonatal and intensive care units of
national health clinics or in private clinics. The
increase in the rate of identification of these
disorders is directly related to clinical judgement
and the habit of thinking of those diseases not
as rarities but as possibilities, in the light of cases
that cannot be explained by more familiar
physiopathologies. From this step forward,
advances in knowledge and biochemical
techniques will really be able to increase the
rate of diagnosis.
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RESUMO
CONTEXTO: Os erros inatos do metabolismo (EIM) causam as doenças metabólicas hereditárias (DMH) e classicamente
resultam da falta de atividade de uma ou mais enzimas específicas ou defeitos no transporte de proteínas. OBJETIVOS: Revisão
clínica sobre Erros Inatos do Metabolismo (EIM) voltada para o médico na sua prática diária, com tabelas e figuras que
sumariam as diversas doenças que fazem parte deste assunto. Uma pequena revisão das bases bioquímicas suficiente para
compreensão da fisiopatologia dos EIM. FONTES DOS DADOS: Pesquisa bibliográfica utilizando livros de textos  sobre os
EIM e suas bases bioquímicas (Scriver, CR et al, 1995), revisão da literatura que abrangeu os artigos clássicos e aqueles
publicados  nos últimos dez anos, fornecendo assim referências atualizadas sobre as diversas doenças metabólicas hereditárias
(DMH). SELEÇÃO DOS ESTUDOS: Foi realizada seleção de textos de autores consagrados pelo conhecimento e experiência
na área dos EIM e descrição de casos clínicos com suas manifestações clínicas mais peculiares e marcantes. SÍNTESE DOS
DADOS: Os EIM são doenças subdiagnosticadas pela falta de hábito do médico geral, neonatologista e intensivista em pensar
nesta hipótese. Na revisão são descritos os mecanismos de herança, as principais características clínicas e os achados
laboratoriais dos EIM, dentro de uma classificação que fornece uma visão geral sobre o assunto. São abordadas sumariamente
as formas de tratamento existentes para os diversos grupos de EIM. CONCLUSÕES: Os EIM não são doenças raras como se
pensava no passado e pacientes portadores de DMH fazem parte do atendimento geral nos pronto-atendimentos, nas clínicas
cirúrgicas, obstétricas, pediátricas, neurológicas e psiquiátricas, aguardando diagnóstico, prognóstico e tratamento terapêutico
e/ou de suporte.
PALAVRAS-CHAVE:  Erros inatos do  metabolismo. Doença metabólica hereditária. Diagnóstico.
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